The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
P/E ratio for The Oncology Institute, Inc. (TOI)
P/E ratio as of 2023: -1.81
According to The Oncology Institute, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.81. At the end of 2022 the company had a P/E ratio of 72.49.
P/E ratio history for The Oncology Institute, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.81 |
| 2022 | 72.49 |
| 2021 | -59.10 |
| 2020 | -44.58 |
| 2019 | -155.45 |
| 2018 | 70.64 |